Dr Mintun will report to Daniel Skovronsky, president and CEO of the company. Most recently, he has worked as the vice chair for research and director of the Center for Clinical Imaging Research at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis, MO.
Dr Skovronsky said: “I am very excited that someone of Mark’s reputation and stature is joining Avid. Mark will be a valuable addition to our leadership team. He will bring significant academic credentials as well as strong leadership to Avid.”
Dr Mintun said: “Avid has shown great leadership in the development of new molecular imaging agents, including florbetapir F 18, the first amyloid imaging agent for detection of a hallmark pathology of Alzheimer’s disease to complete Phase III clinical development.
“I am excited to be joining the Avid team where I will be involved with the clinical development of florbetapir as well as focusing on our pipeline which includes projects aimed at addressing unmet needs in Parkinson’s disease, Dementia with Lewy bodies and in diabetes.”
